The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: Relevance to Alzheimer's disease
Abstract
Alzheimer's disease (AD) is associated with major impairments in insulin and insulin-like growth factor (IGF) gene expression and signaling in the brain. These abnormalities increase with severity of dementia, and are associated with deficiencies in energy metabolism and acetylcholine homeostasis. The co-existence of brain insulin/IGF deficiency and resistance suggests that AD may represent a brain-specific form of diabetes, i.e. Type 3 diabetes. This hypothesis is supported by the findings in an experimental animal model in which intracerebral (ic) Streptozotocin (STZ) was used to deplete brain and not pancreatic insulin. The ic-STZ treatment produced brain-specific insulin depletion and insulin resistance are associated with progressive neurodegeneration that shares many features in common with AD. We now demonstrate that early treatment with peroxisome-proliferator activated receptor agonists can effectively prevent ic-STZ-induced neurodegeneration and its associated deficits in learning and memory. These effects were mediated by increased binding to insulin receptors, reduced levels of oxidative stress and tau phosphorylation, and increased choline acetyltransferase expression in the brain, suggesting that insulin sensitizer agents may have therapeutic efficacy in early AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas
Szkudelski, T. (2001) · Physiological Research · doi:10.33549/physiolres.930111 · Cited by 2,876
Steen, E., Terry, B. M., J. Rivera, E., Cannon, J. L., Neely, T. R., Tavares, R., Xu, X. J., Wands, J. R., & de la Monte, S. M. (2005) · Journal of Alzheimer's Disease · doi:10.3233/jad-2005-7107 · Cited by 1,703 · cited 7×
“A β PP, and increased levels of phospho-tau in advanced AD relative to normal aging [2].”
InfluentialSelf-citationConversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration
Patrick, G. N., Zukerberg, L., Nikolic, M., de la Monte, S., Dikkes, P., & Tsai, L.-H. (1999) · Nature · doi:10.1038/45159 · Cited by 1,545
Self-citationTau pathology in Alzheimer disease and other tauopathies
Iqbal, K., del C. Alonso, A., Chen, S., Chohan, M. O., El-Akkad, E., Gong, C.-X., Khatoon, S., Li, B., Liu, F., Rahman, A., et al. (2005) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2004.09.008 · Cited by 1,037
Sayre, L. M., Zelasko, D. A., Harris, P. L. R., Perry, G., Salomon, R. G., & Smith, M. A. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.68052092.x · Cited by 1,007
Senile dementia of the Alzheimer type
Terry, R. D., & Katzman, R. K. (1983) · Annals of Neurology · doi:10.1002/ana.410140502 · Cited by 829
Oxidative Alterations in Alzheimer's Disease
Markesbery, W. R., & Carney, J. M. (1999) · Brain Pathology · doi:10.1111/j.1750-3639.1999.tb00215.x · Cited by 784
The role of inflammation in Alzheimer’s disease
Tuppo, E. E., & Arias, H. R. (2005) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2004.07.009 · Cited by 734
Rivera, E. J., Goldin, A., Fulmer, N., Tavares, R., Wands, J. R., & de la Monte, S. M. (2005) · Journal of Alzheimer s Disease · doi:10.3233/jad-2005-8304 · Cited by 723 · cited 10×
“Recently, we demonstrated that ChAT gene expression was regulated by insulin and IGF-1 stimulation, and that in AD as well as in the ic-STZ model, impaired insulin and IGF-1 signaling mechanisms correlate with deficits in acetylcholine production [3].”
InfluentialRole for neuronal insulin resistance in neurodegenerative diseases
Schubert, M., Gautam, D., Surjo, D., Ueki, K., Baudler, S., Schubert, D., Kondo, T., Alber, J., Galldiks, N., Küstermann, E., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308724101 · Cited by 637
Cited by
Querfurth, H. W., & LaFerla, F. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0909142 · Cited by 4,569
Cognitive decline and dementia in diabetes mellitus: mechanisms and clinical implications
Biessels, G. J., & Despa, F. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0048-7 · Cited by 1,454
Alzheimer’s disease is type 3 diabetes—Evidence reviewed
de la Monte, S. M., & Wands, J. R. (2008) · Journal of Diabetes Science and Technology · doi:10.1177/193229680800200619 · Cited by 1,158
Self-citationHypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus
Whitmer, R. A. (2009) · JAMA · doi:10.1001/jama.2009.460 · Cited by 1,128
Is Alzheimer’s disease a type 3 diabetes? A critical appraisal
Kandimalla, R., Thirumala, V., & Reddy, P. H. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2016.08.018 · Cited by 621
Amyloid beta oligomers induce impairment of neuronal insulin receptors
Zhao, W., De Felice, F. G., Fernandez, S., Chen, H., Lambert, M. P., Quon, M. J., Krafft, G. A., & Klein, W. L. (2008) · The FASEB Journal · doi:10.1096/fj.06-7703com · Cited by 587
Hyperinsulinemia Drives Diet-Induced Obesity Independently of Brain Insulin Production
Mehran, A. E., Templeman, N. M., Brigidi, G. S., Lim, G. E., Chu, K.-Y., Hu, X., Botezelli, J. D., Asadi, A., Hoffman, B. G., Kieffer, T. J., et al. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.10.019 · Cited by 498
Brain metabolic dysfunction at the core of Alzheimer's disease
de la Monte, S. M., & Tong, M. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.12.012 · Cited by 461
Self-citationBrain Insulin Resistance and Deficiency as Therapeutic Targets in Alzheimers Disease
M. de la Monte, S. (2012) · Current Alzheimer Research · doi:10.2174/156720512799015037 · Cited by 448
Insulin resistance and Alzheimer's disease
De La Monte, S. M. (2009) · BMB Reports · doi:10.5483/bmbrep.2009.42.8.475 · Cited by 392
Grieb, P. (2016) · Molecular Neurobiology · doi:10.1007/s12035-015-9132-3 · Cited by 361
Kim, B., & Feldman, E. L. (2015) · Experimental & Molecular Medicine · doi:10.1038/emm.2015.3 · Cited by 355
Sharma, P., Srivastava, P., Seth, A., Tripathi, P. N., Banerjee, A. G., & Shrivastava, S. K. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2018.12.006 · Cited by 331
de la Monte, S. M. (2017) · Drugs · doi:10.1007/s40265-016-0674-0 · Cited by 331
Type 3 diabetes is sporadic Alzheimer׳s disease: Mini-review
de la Monte, S. M. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.06.008 · Cited by 313
Self-citationDiabetes mellitus and Alzheimer's disease: GSK-3β as a potential link
Zhang, Y., Huang, N.-Q., Yan, F., Jin, H., Zhou, S.-Y., Shi, J.-S., & Jin, F. (2018) · Behavioural Brain Research · doi:10.1016/j.bbr.2017.11.015 · Cited by 301
Zhao, W.-Q., & Townsend, M. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.10.014 · Cited by 291
Bosco, D., Fava, A., Plastino, M., Montalcini, T., & Pujia, A. (2011) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2011.01318.x · Cited by 283
Should Depressive Syndromes Be Reclassified as “Metabolic Syndrome Type II”?
McIntyre, R. S., Soczynska, J. K., Konarski, J. Z., Woldeyohannes, H. O., Law, C. W. Y., Miranda, A., Fulgosi, D., & Kennedy, S. H. (2007) · Annals of Clinical Psychiatry · doi:10.1080/10401230701653377 · Cited by 277
“The salience of insulin disturbances to the pathophysiology of Alzheimer’s disease has provided the basis for the nosology of “type III diabetes” (63).”
BackgroundSalkovic-Petrisic, M., Knezovic, A., Hoyer, S., & Riederer, P. (2013) · Journal of Neural Transmission · doi:10.1007/s00702-012-0877-9 · Cited by 272
de la Monte, S. M. (2012) · Drugs · doi:10.2165/11597760-000000000-00000 · Cited by 265
“PPARd, may be needed to treat neurodegeneration since PPARd is abundantly expressed in the brain, and previous studies showed that PPARd agonists more effectively prevented neurocognitive deficits and AD-type neurodegeneration, including AbPP expression and AbPP-Ab accumulation, compared with PPARa and PPARg agonists;…”
BackgroundResultInfluentialDynamics of diabetes and obesity: Epidemiological perspective
Boles, A., Kandimalla, R., & Reddy, P. H. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.01.016 · Cited by 263
Nicolakakis, N., Aboulkassim, T., Ongali, B., Lecrux, C., Fernandes, P., Rosa-Neto, P., Tong, X.-K., & Hamel, E. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.3348-08.2008 · Cited by 262
Protein O-GlcNAcylation in diabetes and diabetic complications
Ma, J., & Hart, G. W. (2013) · Expert Review of Proteomics · doi:10.1586/14789450.2013.820536 · Cited by 252
White, C. L., Pistell, P. J., Purpera, M. N., Gupta, S., Fernandez-Kim, S.-O., Hise, T. L., Keller, J. N., Ingram, D. K., Morrison, C. D., & Bruce-Keller, A. J. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.04.002 · Cited by 245
“…reminiscent of Alzheimer’s -type neurodegeneration can be produced experimentally by selectively impairing insulin/IGF functions in the brain (LesterColl et al., 2006), and it has even been suggested that Alzheimer’s disease could represent a type 3 form of diabetes (de la Monte et al., 2006).”
Freude, S., Hettich, M. M., Schumann, C., Stöhr, O., Koch, L., Köhler, C., Udelhoven, M., Leeser, U., Müller, M., Kubota, N., et al. (2009) · The FASEB Journal · doi:10.1096/fj.09-132043 · Cited by 218
Insulin-resistant brain state: The culprit in sporadic Alzheimer's disease?
Correia, S. C., Santos, R. X., Perry, G., Zhu, X., Moreira, P. I., & Smith, M. A. (2011) · Ageing Research Reviews · doi:10.1016/j.arr.2011.01.001 · Cited by 212
The Insulin/Akt Signaling Pathway Is Targeted by Intracellular β-Amyloid
Lee, H.-K., Kumar, P., Fu, Q., Rosen, K. M., & Querfurth, H. W. (2009) · Molecular Biology of the Cell · doi:10.1091/mbc.e08-07-0777 · Cited by 185
Beeri, M. S., Schmeidler, J., Silverman, J. M., Gandy, S., Wysocki, M., Hannigan, C. M., Purohit, D. P., Lesser, G., Grossman, H. T., & Haroutunian, V. (2008) · Neurology · doi:10.1212/01.wnl.0000324925.95210.6d · Cited by 157
Limited Alzheimer-type neurodegeneration in experimental obesity and type 2 diabetes mellitus
Moroz, N., Tong, M., Longato, L., Xu, H., & de la Monte, S. M. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-15103 · Cited by 151
Endurance factors improve hippocampal neurogenesis and spatial memory in mice
Kobilo, T., Yuan, C., & van Praag, H. (2011) · Learning & Memory · doi:10.1101/lm.2001611 · Cited by 114
McIntyre, R. S., Soczynska, J. K., Woldeyohannes, H. O., Miranda, A., Vaccarino, A., MacQueen, G., Lewis, G. F., & Kennedy, S. H. (2012) · Bipolar Disorders · doi:10.1111/bdi.12006 · Cited by 104
Vascular and metabolic dysfunction in Alzheimer’s disease: a review
Murray, I. V. J., Proza, J. F., Sohrabji, F., & Lawler, J. M. (2011) · Experimental Biology and Medicine · doi:10.1258/ebm.2011.010355 · Cited by 104
Meakin, P. J., Harper, A. J., Hamilton, D. L., Gallagher, J., McNeilly, A. D., Burgess, L. A., Vaanholt, L. M., Bannon, K. A., Latcham, J., Hussain, I., et al. (2012) · Biochemical Journal · doi:10.1042/bj20110512 · Cited by 103
Depression and Cognitive Impairment—Extrahepatic Manifestations of NAFLD and NASH
Colognesi, M., Gabbia, D., & De Martin, S. (2020) · Biomedicines · doi:10.3390/biomedicines8070229 · Cited by 98
Nuclear receptors in neurodegenerative diseases
Skerrett, R., Malm, T., & Landreth, G. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.05.019 · Cited by 94
Malm, T., Mariani, M., Donovan, L. J., Neilson, L., & Landreth, G. E. (2015) · Journal of Neuroinflammation · doi:10.1186/s12974-014-0229-9 · Cited by 77
Ho, L., Yemul, S., Knable, L., Katsel, P., Zhao, R., Haroutunian, V., & Pasinetti, G. M. (2012) · International Journal of Alzheimer's Disease · doi:10.1155/2012/321280 · Cited by 21
Querfurth, H., Marshall, J., Parang, K., Rioult-Pedotti, M. S., Tiwari, R., Kwon, B., Reisinger, S., & Lee, H.-K. (2022) · PLOS ONE · doi:10.1371/journal.pone.0261696 · Cited by 9
Metadata
- Authors
- de la Monte, S. M., Tong, M., Lester-Coll, N., Plater, Jr., & Wands, J. R.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2006-09-08
- Volume
- 10
- Issue
- 1
- Pages
- 89-109
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W1711248712
- Cited by
- 325
- References
- 29
- FWCI
- 9.80
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.